Currently, the peripheral CB1R antagonist monlunabant (MRI-1891, INV-202) is reported to be advancing to the phase IIB clinical stage after successfully completing phase IB (NCT05282446) and IIA (NCT05891834) studies in obesity and metabolic syndrome (12). Here, CNR1 is linked to obesity disorder.